SEC Form 4 · accession 0001144204-15-053019
BRAINSTORM CELL THERAPEUTICS INC. · BCLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Uri Yablonka
Officer — Chief Operating Officer · Director
Period of report
Aug 27, 2015
Accepted (ET)
Aug 31, 2015 · 4:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001137883
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.75 | Aug 27, 2015 | A | 13,333 | A | Sep 27, 2015 | Aug 27, 2025 | Common Stock | 13,333 | 13,333 | D |
Explanation of responses
- F1Option vests and becomes exercisable in 12 consecutive, equal monthly installments commencing on September 27, 2015 until fully vested and exercisable on August 27, 2016, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date.